GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Cash Flow from Discontinued Operations

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Cash Flow from Discontinued Operations : NT$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Great Novel Therapeutics Biotech & Medicals's cash flow from discontinued operations for the six months ended in Dec. 2023 was NT$0.00 Mil. It means Great Novel Therapeutics Biotech & Medicals received NT$0.00 Mil from the sale of part of business quarterly. Great Novel Therapeutics Biotech & Medicals's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.00 Mil.


Great Novel Therapeutics Biotech & Medicals Cash Flow from Discontinued Operations Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Cash Flow from Discontinued Operations Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Discontinued Operations
Get a 7-Day Free Trial - - - - -

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Great Novel Therapeutics Biotech & Medicals Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Great Novel Therapeutics Biotech & Medicals Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines